在胃癌中,yp阶段和p阶段之间的生存时间比较
Keisuke Komori1,2, Takanobu Yamada3,2, Shuji Ando4
1Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Anticancer research
|May 31, 2024
概括
晚期胃癌的新辅助化疗可能会改变生存结果. 化疗后的病态分期 (ypStage) 显示出比没有化疗的病态分期 (pStage) 更糟糕的预后,特别是在晚期.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 可切除的晚期胃癌的标准治疗包括胃切除术与辅助化疗.
- 新辅助化疗正在探索改善生存,但其对阶段和预后的影响尚不清楚.
- 基于化疗后的病态阶段 (ypStage) 与没有化疗的病态阶段 (pStage) 的结果比较至关重要.
研究的目的:
- 评估长期结果,比较胃癌的yp阶段和p阶段.
- 在新辅助化疗后调查最佳辅助化疗强度.
- 为了确定yp阶段和p阶段的标准是否可互换治疗选择.
主要方法:
- 对1585名经过激进胃切除术的胃癌患者 (2007年1月 - 2019年11月) 的回顾性分析.
- 倾向性得分匹配以调整患者背景差异.
- 在ypStage和pStage组之间比较无复发生存率,并进行预后因子分析.
主要成果:
- 在5年无复发存活时间中,对于yp/pStage I (77.1%对90.9%) 和yp/pStage II (50.4%对69.1%) 没有显著差异.
- 对于yp/pStage III (42.9%与68.7%相比,p=0.016) 观察到一个显著的差异.
- 手术前的化疗是yp/pStage I (HR=17.72) 和yp/pStage II (HR=2.655) 的独立预后因素.
结论:
- yp阶段通常表明与p阶段相比,预后更差.
- 对于晚期胃癌,需要进一步开发多学科治疗策略.
- 对于接受新辅助化疗的患者,目前的分期标准可能需要调整.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
01:24Kaplan-Meier Approach
129
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
129
01:20Actuarial Approach
74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74